Mostrando 5 resultados de: 5
Filtros aplicados
Subtipo de publicación
Article(5)
Publisher
Clinical and Vaccine Immunology(1)
Infection and Immunity(1)
Lancet Regional Health - Americas(1)
Med(1)
Science(1)
Antigenicity and immunogenicity of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b
ArticleAbstract: Polysaccharide-protein conjugates as vaccines have proven to be very effective in preventing HaemophPalabras claves:Autores:Cardoso F., Carmenate T., Chang J., Cosme K., Eugenio Hardy, Fernández-Santana V., Figueroa I., Hernández I., Heynngnezz L., Izquierdo M., Mawas F., Musacchio Lasa A., Peña L., Rodriguez A., Rodriguez M.C., Roy R., Toledo-Romani M.E., Valdés Y., Verez-Bencomo V.Fuentes:scopusA synthetic conjugate polysaccharide vaccine against haemophilus influenzae type b
ArticleAbstract: Glycoconjugate vaccines provide effective prophylaxis against bacterial infections. To date, howeverPalabras claves:Autores:Aguilar A., Baly A., Campa C., Cardoso F., Carmenates A., Cosme K., Costa L., Deler M.L., Diaz M., Eugenio Hardy, Fernández-Santana V., Garcia E., Hernández I., Herrera L., Heynngnezz L., Izquierdo M., Medina E., Montane M., Muzachio A., Ramos A., Rodriguez A., Rodriguez M.C., Roy R., Sánchez R., Sosa I., Toledo-Romani M.E., Toraño G., Valdés Y., Verez-Bencomo V., Villar A.Fuentes:scopusPhase I clinical evaluation of a synthetic oligosaccharide-protein conjugate vaccine against Haemophilus influenzae type b in human adult volunteers
ArticleAbstract: Since 1989, we have been involved in the development of a vaccine against Haemophilus influenzae typPalabras claves:Autores:Aguilar A., Alvarez Y., Baly A., Dfana J., Diaz M., Eugenio Hardy, Fernández-Santana V., Hernandez H., Hernández I., Heynngnezz L., Musachio A., Muzio V., Rodriguez A., Rodriguez F., Rodriguez M.C., Sánchez R., Serrano T., Toledo-Romani M.E., Toraño G., Verez-Bencomo V.Fuentes:scopusSafety and immunogenicity of anti-SARS-CoV-2 heterologous scheme with SOBERANA 02 and SOBERANA Plus vaccines: Phase IIb clinical trial in adults
ArticleAbstract: Background: SOBERANA 02 has been evaluated in phase I and IIa studies comparing homologous versus hePalabras claves:Conjugate vaccine, covid-19, heterologous schedule, phase IIb clinical trial, recombinant RBD, Translation to patientsAutores:Acevedo-Martínez Y., Acosta-Martinez M.A., Alfaro-Guzmán A., Amoroto M., Arteaga-García A., Ávila-Cabreja J.A., Baro-Roman G., Bergado-Baez G., Biglari A., Boggiano-Ayo T., Brito-Pascual I., Cardoso-SanJorge F., Chen G.W., Climent-Ruiz Y., Coviella-Artime J.M., Cruz-Sui O., Cubas-Curbelo M., Díaz-Hernández M., Domínguez-Pentón Y.R., Doroud D., Dubed-Echevarría M., Enriquez-Puertas J., Espi-Ávila J., Espino-Rojas N.T., Estoque-Cabrera S., Fernández-Castillo S., Fontanies-Fernández M., Galano-Frutos E., Garcés-Hechavarría A., García-Carmenate M., García-López E., García-Montero M., García-Rivera D., García-Vega Y., Garrido-Arteaga R., Gómez-Maceo Y., González-Mugica R., Guillén-Obregón B., Hernández-Garcia T., Lora-García J., Martínez-Bedoya D., Martínez-Pérez M., Martínez-Rivera R., Medina-Nápoles M., Medinas-Santos G.M., Mendoza-Hernández I., Misladys Rodríguez Ortega, Morales-Ruano S., Morffi-Cinta I., Muñoz Y., Noa-Romero E., Ojito-Magaz E., Ontivero-Pino I., Orosa-Vázquez I., Palenzuela-Diaz A., Paredes-Moreno B., Pérez-Guevara M.T., Perez-Perez A., Pérez-Rodríguez S., Pi-Estopiñán F., Quintero-Moreno L., Ramírez-Gonzalez U., Reyes-Matienzo R., Rivera D.G., Rodríguez-Castillo P.G., Rodriguez-González M., Rodríguez-Noda L., Sanchez-Ramirez B., Santana-Mederos D., Santos-Vega B.L., Sarda-Rodriguez I.L., Toledo-Romani M.E., Valdes-Balbín Y., Valenzuela-Silva C.M., Valera-Fernández R., Verdecia-Sánchez L., Verez-Bencomo V., Zulueta-Pérez L.Fuentes:scopusSafety and efficacy of the two doses conjugated protein-based SOBERANA-02 COVID-19 vaccine and of a heterologous three-dose combination with SOBERANA-Plus: a double-blind, randomised, placebo-controlled phase 3 clinical trial
ArticleAbstract: Background: SOBERANA-02 is a COVID-19 conjugate vaccine (recombinant RBD conjugated to tetanus toxoiPalabras claves:Conjugate-vaccine, COVID-19 Vaccine, Heterologous scheme, RBD-subunit vaccine, SARS-COV-2, Vaccine efficacyAutores:Bacallao-Castillo J.P., Baldoquín-Rodríguez W., Biglari A., Caballero-González E., Climent-Ruiz Y., Doroud D., Duartes-González R., Egües-Torres L., Fernández-Castillo S., Fonte-Galindo O., García-Blanco S., García-Carmenate M., García-Rivera D., González-Mujica Romero R., Gouya M.M., Herrera-Marrero N., Huete-Ferreira S., Idalmis-Cisnero K., Licea-Martín E., Martínez-Pérez M., Meliá-Pérez D., Mendoza-Hernández I., Misladys Rodríguez Ortega, Paredes-Moreno B., Pérez-Cabrera S., Rodríguez-González M., Rojas-Remedios I., Samón-Tabio O., Toledo-Romani M.E., Valdes-Balbín Y., Valenzuela-Silva C.M., Van Der Stuyft P., Velazco-Villares P., Verez-Bencomo V.Fuentes:scopus